Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study

BACKGROUND: Limited prospective data are available on the long-term safety of darbepoetin alfa (DA) for treating anemia in children with chronic kidney disease (CKD). METHODS: In this prospective, phase IV, observational registry study, children ≤16 years of age with CKD anemia and receiving DA were...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaefer, Franz, Hoppe, Bernd, Jungraithmayr, Therese, Klaus, Günter, Pape, Lars, Farouk, Mourad, Addison, Janet, Manamley, Nick, Vondrak, Karel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756039/
https://www.ncbi.nlm.nih.gov/pubmed/26482252
http://dx.doi.org/10.1007/s00467-015-3225-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756039/
https://www.ncbi.nlm.nih.gov/pubmed/26482252
http://dx.doi.org/10.1007/s00467-015-3225-0

Ejemplares similares